Who makes Formatris 24µg?

Formatris 24µg is developed by MEDA Pharma GmbH & Co. KG.

Last reviewed 2026-04-19 · How we verify

Formatris 24µg

MEDA Pharma GmbH & Co. KG · Phase 2 active Small molecule

At a glance

Generic name	Formatris 24µg
Sponsor	MEDA Pharma GmbH & Co. KG
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Formatris 24µg CI brief — competitive landscape report
Formatris 24µg updates RSS · CI watch RSS
MEDA Pharma GmbH & Co. KG portfolio CI